2023-04-03 09:09:47 ET
- Alzamend Neuro ( NASDAQ: ALZN ) has started a phase 1/2a trial of ALZN002, an immunotherapy vaccine for mild to moderate Alzheimer's dementia.
- The trial, which will enroll 20-30 participants, will evaluate the safety, tolerability, and efficacy of ALZN002 at different doses compared to placebo,.
- The company said the purpose of the study is to determine the most appropriate dose before moving the candidate into a larger trial.
- ALZN002 is produced from a patient's own immune system. Alzamend Neuro ( ALZN ) explains it consists of autologous dendritic cells, activated white blood cells that are then engineered outside of the body to attack Alzheimer’s-related amyloid-beta proteins.
- Read why Seeking Alpha's Quant Rating rates Alzamend Neuro ( ALZN ) a strong sell.
For further details see:
Alzamend Neuro begins trial of Alzheimer's immunotherapy vaccine